相关实验视频

Updated: May 15, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

在囊细胞衍生甲状腺癌中CD44变异表达:克服多药耐药性的影响

Benny Mosoane¹, Michelle McCabe¹, Brandon S Jackson²

¹Department of Anatomical Pathology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa.

Molecules (Basel, Switzerland)

|May 14, 2025

概括

CD44变体是甲状腺癌进展和多药性耐药性 (MDR) 的关键. 针对CD44提供了潜在的治疗策略,以改善结果,特别是在资源较少的环境中.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

甲状腺癌 (TC) 给全球健康带来了各种结果的挑战.
由于诊断迟到和医疗保健有限,低资源环境面临更高的死亡率.
来自毛囊细胞的TC亚型 (PTC,FTC,ATC,PDTC) 呈现异质性.

研究的目的:

审查CD44变异在卵泡细胞衍生的甲状腺癌中的作用.
探索CD44对瘤进展和多药耐药性 (MDR) 的影响.
突出潜在的CD44向性治疗策略,用于TC.

主要方法:

文献综述综合了关于TC中CD44表达和功能的现有知识.
分析CD44变体在细胞粘附,迁移,存活和癌症干细胞 (CSC) 维护中的作用.
通过特定的分子通路检查CD44对MDR的贡献.

主要成果:

CD44变体对TC进展和MDR具有关键影响.
不同的CD44异形表达具有诊断,预后和治疗的含义.
CD44v6表达与PTC中的转移相关,并有助于FTC中的差异化.
CD44通过药物流量,亡逃避和CSC维护促进MDR.

结论:

通过抗体或纳米载体向CD44,有望克服TC中的MDR.
有限的研究存在于专门针对TC的CD44向疗法.
需要进一步研究,以制定有效的CD44向策略,以改善TC患者的治疗结果,特别是在高负担地区.

关键词:

在CD44变种中.毛囊细胞衍生的癌症多种药物耐药性多种药物耐药性治疗目标是治疗的目标.甲状腺癌是一种癌症.瘤微环境是一个微环境.

更多相关视频

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...